04-1098 | Anti-phospho-Jak2 (Tyr1007/Tyr1008) Antibody, clone E132, rabbit monoclonal

04-1098
100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RWB, IH(P), ICC, IPRbUnpurifiedMonoclonal Antibody
      Description
      Catalogue Number04-1098
      DescriptionAnti-phospho-Jak2 (Tyr1007/Tyr1008) Antibody, clone E132, rabbit monoclonal
      Alternate Names
      • Janus kinase 2
      • Janus kinase 2 (a protein tyrosine kinase)
      • tyrosine-protein kinase JAK2
      Background InformationJAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor.
      References
      Product Information
      FormatUnpurified
      Control
      • Immunoprecipitation pellets from Jurkat cell lysate +GM-CSF
      PresentationRabbit Monoclonal in buffer containing 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl containing 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
      Applications
      ApplicationPlease note that this product will not be available for sale after March 15, 2015. Please select one of the other antibodies against this target.
      Key Applications
      • Western Blotting
      • Immunohistochemistry (Paraffin)
      • Immunocytochemistry
      • Immunoprecipitation
      Application NotesImmunohistochemistry Analysis: A 1:50-100 dilution from a previous lot detected Jak2 in human lung adenocarcinoma tissue.
      Dot Blot Analysis: Dot Blot analysis from a previous lot detected Jak2 on immunogen phospho-peptide and non-phospho peptide.
      Immunocytochemistry Analysis: A 1:50-100 dilution from a previous lot was used in IC.
      Immunoprecipitation Analysis: A 1:50 dilution from a previous lot was used in IP.

      Biological Information
      ImmunogenPhospho-synthetic peptide corresponding to residues surrounding Tyr1007 and Tyr1008 of human Jak2.
      EpitopePhosphorylated Tyr1007/Tyr1008
      CloneE132
      HostRabbit
      SpecificityThe antibody only detects Jak2 phosphorylated on Tyr1007 and Tyr1008.
      IsotypeIgG
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • EC 2.7.10.2
      • JAK-2
      • JTK10
      • OTTHUMP00000021024
      • OTTHUMP00000043260
      Modifications
      • Phosphorylation
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION:Plays a role in leptin signaling and control of body weight By similarity. Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.
      CATALYTIC ACTIVITY:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
      SUBUNIT STRUCTURE: Interacts with SIRPA and SH2B1 By similarity. Interacts with IL23R, SKB1 and STAM2.
      SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane protein By similarity. Note: Wholly intracellular, possibly membrane associated By similarity.
      TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node.
      DOMAIN: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain By similarity, while the presence of slight differences suggest a different role for domain 1.
      PTM:Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813 By similarity.
      INVOLVEMENT IN DISEASE: Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.
      Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.
      Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
      Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
      Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
      SEQUENCE SIMILARITIES:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
      Contains 1 FERM domain.
      Contains 1 protein kinase domain.
      Contains 1 SH2 domain.
      Molecular Weight~130 kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blot on immunoprecipitation pellets from Jurkat cell lysate +GM-CSF.
      Western Blot Analysis: A 1:5,000-10,000 dilution of this antibody was used to detect Jak2 in immunoprecipitation pellets from Jurkat cell lysate +GM-CSF.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20ºC from date of receipt.
      Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      SDS

      Title

      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - NG1811035 NG1811035
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - 1988583 1988583
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - 2036711 2036711
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - 2161249 2161249
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - 2328400 2328400
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - JH1753741 JH1753741
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - NG1685066 NG1685066
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - NG1734255 NG1734255
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - NG1846037 NG1846037
      Anti-phospho-Jak2 (Tyr1007/Tyr1008), clone E132, Rabbit Monoclonal - NG1875685 NG1875685

      References

      Reference overviewPub Med ID
      HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.
      Tao, W; Chakraborty, SN; Leng, X; Ma, H; Arlinghaus, RB
      Genes & cancer  6  19-29  2015

      Show Abstract
      25821558 25821558
      A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs.
      Cheng, F; Lienlaf, M; Wang, HW; Perez-Villarroel, P; Lee, C; Woan, K; Rock-Klotz, J; Sahakian, E; Woods, D; Pinilla-Ibarz, J; Kalin, J; Tao, J; Hancock, W; Kozikowski, A; Seto, E; Villagra, A; Sotomayor, EM
      Journal of immunology (Baltimore, Md. : 1950)  193  2850-62  2014

      Show Abstract
      25108026 25108026
      c-Abl activates janus kinase 2 in normal hematopoietic cells.
      Tao, W; Leng, X; Chakraborty, SN; Ma, H; Arlinghaus, RB
      The Journal of biological chemistry  289  21463-72  2014

      Show Abstract
      24923444 24923444

      Brochure

      Title
      Pathways and Biomarkers of JAK/STAT Signaling

      Technical Info

      Title
      JAK/STAT Signaling Research Focus

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      04-001 Anti-JAK2 Antibody, clone 8E10.2 Show Pricing & Availability
      06-255 Anti-JAK2 Antibody Show Pricing & Availability
      07-606 Anti-phospho-JAK2 (Tyr1007/1008) Antibody Show Pricing & Availability
      09-203 Anti-phospho-JAK2 (Tyr868) Antibody Show Pricing & Availability
      09-241 Anti-phospho JAK-2 (Tyr570) Antibody Show Pricing & Availability
      09-242 Anti-phospho JAK-2 (Tyr813) Antibody Show Pricing & Availability
      09-243 Anti-phospho JAK2 (Tyr972) Antibody Show Pricing & Availability
      09-275 Anti-phospho-JAK2 (Tyr1007/1008) Antibody Show Pricing & Availability
      16-121 Anti-JAK2 Antibody, agarose conjugate Show Pricing & Availability
      MABS809 Anti-JAK2, clone 1C1 Antibody Show Pricing & Availability

      Product Families

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies